Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Letter: immune checkpoint inhibitor-induced colitis-shouldn't we be checking more often?

Samaan MA, Powell N, Irving PM.

Aliment Pharmacol Ther. 2019 Aug;50(4):472-473. doi: 10.1111/apt.15393. No abstract available.

PMID:
31359485
2.

Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn's Disease.

Taylor KM, Hanscombe KB, Prescott NJ, Iniesta R, Traylor M, Taylor NS, Fong S, Powell N, Irving PM, Anderson SH, Mathew CG, Lewis CM, Sanderson JD.

Clin Gastroenterol Hepatol. 2019 Jun 14. pii: S1542-3565(19)30643-3. doi: 10.1016/j.cgh.2019.05.061. [Epub ahead of print]

PMID:
31202982
3.

Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet.

Staudacher HM, Ralph FSE, Irving PM, Whelan K, Lomer MCE.

J Acad Nutr Diet. 2019 Apr 24. pii: S2212-2672(18)31829-X. doi: 10.1016/j.jand.2019.01.017. [Epub ahead of print]

PMID:
31029650
4.

Positioning biologics and new therapies in the management of inflammatory bowel disease.

Honap S, Cunningham G, Tamilarasan AG, Irving PM.

Curr Opin Gastroenterol. 2019 Apr 22. doi: 10.1097/MOG.0000000000000546. [Epub ahead of print]

PMID:
31021925
5.

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27.

6.

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group.

Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27.

PMID:
30824404
7.

A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study.

Cummings F, Gaya DR, Levison S, Subramanian S, Owen G, Rathmell A, Glen F, Demuth D, Meadowcroft S, Irving PM.

Medicine (Baltimore). 2019 Mar;98(9):e14681. doi: 10.1097/MD.0000000000014681.

8.

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.

Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC, Beaugerie L, Bewshea CM, Cole AT, Cummings FR, Daly MJ, Ellul P, Fedorak RN, Festen EAM, Florin TH, Gaya DR, Halfvarson J, Hart AL, Heerasing NM, Hendy P, Irving PM, Jones SE, Koskela J, Lindsay JO, Mansfield JC, McGovern D, Parkes M, Pollok RCG, Ramakrishnan S, Rampton DS, Rivas MA, Russell RK, Schultz M, Sebastian S, Seksik P, Singh A, So K, Sokol H, Subramaniam K, Todd A, Annese V, Weersma RK, Xavier R, Ward R, Weedon MN, Goodhand JR, Kennedy NA, Ahmad T; IBD Pharmacogenetics Study Group.

JAMA. 2019 Feb 26;321(8):773-785. doi: 10.1001/jama.2019.0709. Erratum in: JAMA. 2019 Apr 23;321(16):1636.

PMID:
30806694
9.

Golimumab in the treatment of ulcerative colitis.

Cunningham G, Samaan MA, Irving PM.

Therap Adv Gastroenterol. 2019 Jan 28;12:1756284818821266. doi: 10.1177/1756284818821266. eCollection 2019. Review.

10.

Correction of Defective T-Regulatory Cells From Patients With Crohn's Disease by Ex Vivo Ligation of Retinoic Acid Receptor-α.

Goldberg R, Scotta C, Cooper D, Nissim-Eliraz E, Nir E, Tasker S, Irving PM, Sanderson J, Lavender P, Ibrahim F, Corcoran J, Prevost T, Shpigel NY, Marelli-Berg F, Lombardi G, Lord GM.

Gastroenterology. 2019 May;156(6):1775-1787. doi: 10.1053/j.gastro.2019.01.025. Epub 2019 Jan 30.

PMID:
30710527
11.

Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study.

Samaan MA, Forsyth K, Segal JP, De Jong D, Vleugels JLA, Elkady S, Kabir M, Campbell S, Kok K, Armstrong DG, Penez L, Arenaza AP, Seward E, Vega R, Mehta S, Rahman F, McCartney S, Bloom S, Patel K, Pollok R, Westcott E, Darakhshan A, Williams A, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Dekker E, D'Haens GR, Hart A, Irving PM.

J Crohns Colitis. 2019 May 27;13(6):735-743. doi: 10.1093/ecco-jcc/jjy225.

PMID:
30590513
12.

The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness.

Melandri D, Zlatareva I, Chaleil RAG, Dart RJ, Chancellor A, Nussbaumer O, Polyakova O, Roberts NA, Wesch D, Kabelitz D, Irving PM, John S, Mansour S, Bates PA, Vantourout P, Hayday AC.

Nat Immunol. 2018 Dec;19(12):1352-1365. doi: 10.1038/s41590-018-0253-5. Epub 2018 Nov 12.

PMID:
30420626
13.

Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?

Samaan MA, Arkir Z, Ahmad T, Irving PM.

Expert Opin Biol Ther. 2018 Dec;18(12):1271-1279. doi: 10.1080/14712598.2018.1537367. Epub 2018 Oct 24.

PMID:
30339466
14.

Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity.

de Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA.

Inflamm Bowel Dis. 2019 Apr 11;25(5):937-944. doi: 10.1093/ibd/izy325.

PMID:
30329045
15.

Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study.

Segal JP, Penez L, Mohsen Elkady S, Worley GHT, McLaughlin SD, Mullish BH, Quraishi MN, Ding NS, Glyn T, Kandiah K, Samaan MA, Irving PM, Faiz OD, Clark SK, Hart AL.

Scand J Gastroenterol. 2018 Sep;53(9):1051-1058. doi: 10.1080/00365521.2018.1496271. Epub 2018 Sep 29.

PMID:
30270685
16.

Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Samaan MA, Pavlidis P, Digby-Bell J, Johnston EL, Dhillon A, Paramsothy R, Akintimehin AO, Medcalf L, Chung-Faye G, DuBois P, Koumoutsos I, Powell N, Anderson SHC, Sanderson J, Hayee BH, Irving PM.

Frontline Gastroenterol. 2018 Jul;9(3):221-231. doi: 10.1136/flgastro-2017-100895. Epub 2017 Oct 11.

17.

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).

Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM.

BMJ Open Gastroenterol. 2018 Jul 7;5(1):e000212. doi: 10.1136/bmjgast-2018-000212. eCollection 2018.

18.

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C, Lindsay JO, Taylor A, Barron R, Wright S.

Inflamm Bowel Dis. 2018 Mar 19;24(4):714-724. doi: 10.1093/ibd/izy002.

PMID:
29538683
19.

Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.

Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM.

Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):222-234. doi: 10.1038/nrgastro.2018.14. Epub 2018 Mar 7. Review.

PMID:
29512649
20.

Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M.

United European Gastroenterol J. 2018 Mar;6(2):310-321. doi: 10.1177/2050640617708952. Epub 2017 May 8.

21.

Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All.

Melmed GY, Kaplan GG, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, Siegel CA.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1829-1831. doi: 10.1016/j.cgh.2018.02.036. Epub 2018 Mar 2.

PMID:
29505910
22.

Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review.

Goldenberg SD, Batra R, Beales I, Digby-Bell JL, Irving PM, Kellingray L, Narbad A, Franslem-Elumogo N.

Infect Dis Ther. 2018 Mar;7(1):71-86. doi: 10.1007/s40121-018-0189-y. Epub 2018 Feb 15. Review.

23.

The challenges of control groups, placebos and blinding in clinical trials of dietary interventions.

Staudacher HM, Irving PM, Lomer MCE, Whelans K.

Proc Nutr Soc. 2017 Nov;76(4):628. doi: 10.1017/S0029665117002816. Epub 2017 Aug 31. No abstract available.

PMID:
28854992
24.

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Samaan MA, Pavlidis P, Johnston E, Warner B, Digby-Bell J, Koumoutsos I, Fong S, Goldberg R, Patel K, Gulati S, Medcalf L, Sastrillo M, Brown-Clarke C, Bidewell-Sullivan J, Forsyth K, Lee E, Stanton A, Duncan J, Chung-Faye G, Dubois P, Powell N, Anderson S, Sanderson J, Hayee B, Irving PM.

Frontline Gastroenterol. 2017 Jul;8(3):196-202. doi: 10.1136/flgastro-2016-100720. Epub 2016 Aug 10.

25.

Utilisation of anti-TNF levels in a UK tertiary IBD centre.

Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson JD, Arkir Z, Irving PM.

Frontline Gastroenterol. 2017 Jul;8(3):189-195. doi: 10.1136/flgastro-2016-100739. Epub 2016 Nov 29.

26.
27.

Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply.

Ward MG, Irving PM.

Aliment Pharmacol Ther. 2017 Aug;46(4):465. doi: 10.1111/apt.14209. No abstract available.

28.

Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome.

O'Keeffe M, Jansen C, Martin L, Williams M, Seamark L, Staudacher HM, Irving PM, Whelan K, Lomer MC.

Neurogastroenterol Motil. 2018 Jan;30(1). doi: 10.1111/nmo.13154. Epub 2017 Jul 14.

PMID:
28707437
29.

Optimising use of thiopurines in inflammatory bowel disease.

Dart RJ, Irving PM.

Expert Rev Clin Immunol. 2017 Sep;13(9):877-888. doi: 10.1080/1744666X.2017.1351298. Epub 2017 Jul 12. Review.

PMID:
28678626
30.

The challenges of control groups, placebos and blinding in clinical trials of dietary interventions.

Staudacher HM, Irving PM, Lomer MCE, Whelan K.

Proc Nutr Soc. 2017 Aug;76(3):203-212. doi: 10.1017/S0029665117000350. Epub 2017 Jun 20. Review.

PMID:
28629483
31.

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.

Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K.

Gastroenterology. 2017 Oct;153(4):936-947. doi: 10.1053/j.gastro.2017.06.010. Epub 2017 Jun 15.

PMID:
28625832
32.

Thioguanine in inflammatory bowel disease: Long-term efficacy and safety.

Ward MG, Patel KV, Kariyawasam VC, Goel R, Warner B, Elliott TR, Blaker PA, Irving PM, Marinaki AM, Sanderson JD.

United European Gastroenterol J. 2017 Jun;5(4):563-570. doi: 10.1177/2050640616663438. Epub 2016 Aug 1.

33.

Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial.

Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K.

J Crohns Colitis. 2017 Dec 4;11(12):1420-1429. doi: 10.1093/ecco-jcc/jjx073.

PMID:
28525543
34.

Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.

Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM.

Aliment Pharmacol Ther. 2017 Jul;46(2):150-161. doi: 10.1111/apt.14124. Epub 2017 May 8.

35.

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.

Dart RJ, Samaan MA, Powell N, Irving PM.

Clin Exp Gastroenterol. 2017 Mar 3;10:57-66. doi: 10.2147/CEG.S110547. eCollection 2017. Review.

36.

ECCO IBD Curriculum.

Lindsay JO, Irving PM, Mantzaris GJ, Panés J; ECCO Education Committee and ECCO Governing Board.

J Crohns Colitis. 2017 Sep 1;11(9):1039-1043. doi: 10.1093/ecco-jcc/jjx004. No abstract available.

PMID:
28172611
37.

Patient optimization for surgery relating to Crohn's disease.

Patel KV, Darakhshan AA, Griffin N, Williams AB, Sanderson JD, Irving PM.

Nat Rev Gastroenterol Hepatol. 2016 Dec;13(12):707-719. doi: 10.1038/nrgastro.2016.158. Epub 2016 Oct 26. Review.

PMID:
27780971
38.

Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments.

Di Marco Barros R, Roberts NA, Dart RJ, Vantourout P, Jandke A, Nussbaumer O, Deban L, Cipolat S, Hart R, Iannitto ML, Laing A, Spencer-Dene B, East P, Gibbons D, Irving PM, Pereira P, Steinhoff U, Hayday A.

Cell. 2016 Sep 22;167(1):203-218.e17. doi: 10.1016/j.cell.2016.08.030. Epub 2016 Sep 15.

39.

Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.

Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA.

Clin Gastroenterol Hepatol. 2016 Sep;14(9):1302-9. doi: 10.1016/j.cgh.2016.05.010. Epub 2016 May 14.

PMID:
27189916
40.

The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future.

Samaan MA, Irving PM.

Expert Opin Biol Ther. 2016 Aug;16(8):975-7. doi: 10.1080/14712598.2016.1189529. Epub 2016 May 31. No abstract available.

PMID:
27186809
41.

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel.

Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA.

Inflamm Bowel Dis. 2016 Jun;22(6):1418-24. doi: 10.1097/MIB.0000000000000764.

PMID:
27057680
42.

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Ward MG, Irving PM, Sparrow MP.

World J Gastroenterol. 2015 Oct 28;21(40):11331-42. doi: 10.3748/wjg.v21.i40.11331. Review.

43.

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.

Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME.

Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.

44.

Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease.

Ward MG, Kariyawasam VC, Mogan SB, Patel KV, Pantelidou M, Sobczyńska-Malefora A, Porté F, Griffin N, Anderson SH, Sanderson JD, Harrington DJ, Irving PM.

Inflamm Bowel Dis. 2015 Dec;21(12):2839-47. doi: 10.1097/MIB.0000000000000559.

PMID:
26296064
45.

Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation.

Powell N, Lo JW, Biancheri P, Vossenkämper A, Pantazi E, Walker AW, Stolarczyk E, Ammoscato F, Goldberg R, Scott P, Canavan JB, Perucha E, Garrido-Mesa N, Irving PM, Sanderson JD, Hayee B, Howard JK, Parkhill J, MacDonald TT, Lord GM.

Gastroenterology. 2015 Aug;149(2):456-67.e15. doi: 10.1053/j.gastro.2015.04.017. Epub 2015 Apr 25.

46.

Toxicity and response to thiopurines in patients with inflammatory bowel disease.

Goldberg R, Irving PM.

Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):891-900. doi: 10.1586/17474124.2015.1039987. Epub 2015 Apr 27. Review.

PMID:
25915575
47.

Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome.

Whigham L, Joyce T, Harper G, Irving PM, Staudacher HM, Whelan K, Lomer MC.

J Hum Nutr Diet. 2015 Dec;28(6):687-96. doi: 10.1111/jhn.12318. Epub 2015 Apr 14.

PMID:
25871564
48.

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.

Canavan JB, Scottà C, Vossenkämper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, Fazekasova H, Irving PM, Sanderson JD, Howard JK, Yagel S, Afzali B, MacDonald TT, Hernandez-Fuentes MP, Shpigel NY, Lombardi G, Lord GM.

Gut. 2016 Apr;65(4):584-94. doi: 10.1136/gutjnl-2014-306919. Epub 2015 Feb 24.

49.

Distinct management issues with Crohn's disease of the small intestine.

Fong SC, Irving PM.

Curr Opin Gastroenterol. 2015 Mar;31(2):92-7. doi: 10.1097/MOG.0000000000000149. Review.

PMID:
25594888
50.

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.

Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, Marriott S, Senanayake SM, Lamb CA, Al-Hilou H, Gaya DR, Irving PM, Mansfield J, Parkes M, Ahmad T, Cummings JR, Arnott ID, Satsangi J, Lobo AJ, Smith M, Lindsay JO, Lees CW.

Aliment Pharmacol Ther. 2014 Dec;40(11-12):1313-23. doi: 10.1111/apt.12980. Epub 2014 Oct 6.

Supplemental Content

Loading ...
Support Center